Objective COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. Results We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs - OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs - OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys / Sen, P; Naveen, R; Houshmand, N; Kia, Sm; Joshi, M; Saha, S; Jagtap, K; Agarwal, V; Nune, A; Nikiphorou, E; Tan, Al; Shinjo, Sk; Ziade, N; Velikova, T; Milchert, M; Parodis, I; Gracia-Ramos, Ae; Cavagna, L; Kuwana, M; Knitza, J; Makol, A; Patel, A; Pauling, Jd; Wincup, C; Barman, B; Tehozol, Eaz; Serrano, Jr; de la Torre, I; Colunga-Pedraza, Ij; Merayo-Chalico, J; Chibuzo, Oc; Katchamart, W; Goo, Pa; Shumnalieva, R; Chen, Ym; Hoff, Ls; El Kibbi, L; Halabi, H; Vaidya, B; Shaharir, Ss; Hasan, Atmt; Dey, D; Gutierrez, Cet; Caballero-Uribe, Cv; Lilleker, Jb; Salim, B; Gheita, T; Chatterjee, T; Distler, O; Saavedra, Ma; Day, J; Chinoy, H; COVAD Study, Grp; Kardes, S; Kardes, Sa; Andreoli, L; Lini, D; Screiber, K; Vince, Mn; Singh, Yp; Ranjan, R; Jain, A; Pandya, Sc; Pilania, Rk; Sharma, A; Manoj, Mm; Gupta, V; Kavadichanda, Cg; Patro, Ps; Ajmani, S; Phatak, S; Goswami, Rp; Chowdhury, Ac; Mathew, Aj; Shenoy, P; Asranna, A; Bommakanti, Kt; Shukla, A; Pande, Ar; Chandwar, K; Ghodke, A; Boro, H; Fazal, Zz; Cansu, Du; Yildirim, R; Gasparyan, Ay; Del Papa, N; Sambataro, G; Fabiola, A; Govoni, M; Parisi, S; Bocci, Eb; Sebastiani, Gd; Fusaro, E; Sebastiani, M; Quartuccio, L; Franceschini, F; Sainaghi, Pp; Orsolini, G; De Angelis, R; Danielli, Mg; Venerito, V; Grignaschi, S; Giollo, A; Alluno, A; Ioannone, F; Fornaro, M; Traboco, Ls; Wibowo, Sak; Loarce-Martos, J; Prieto-Gonzalez, S; Gonzalez, Ra; Yoshida, A; Nakashima, R; Sato, S; Kimura, N; Kaneko, Y; Gono, T; Tomaras, S; Proft, Fn; Holzer, Mt; Gromova, Ma; Aharonov, O; Griger, Z; Hmamouchi, I; El Bouchti, I; Baba, Z; Giannini, M; Maurier, F; Campagne, J; Meyer, A; Langguth, D; Limaye, V; Needham, M; Srivastav, N; Hudson, M; Landon-Cardinal, O; Zuleta, Wgr; Arbelaez, A; Cajas, J; Silva, Jap; Fonseca, Je; Zimba, O; Bohdana, D; Ima-Edomwonyi, U; Dedeke, I; Airenakho, E; Madu, Nh; Yerima, A; Olaosebikan, H; Becky, A; Koussougbo, Od; Palalane, E; So, H; Ugarte-Gil, Mf; Chinchay, L; Bernaola, Jp; Pimentel, V; Fathi, Hm; Mohammed, Rha; Harifi, G; Fuentes-Silva, Y; Cabriza, K; Losanto, J; Colaman, N; Cachafeiro-Vilar, A; Bautista, Gg; Ho, Ejg; Gonzalez, R; Nunez, Ls; Vergara, Mc; Baez, Jt; Alonzo, H; Pastelin, Cbs; Salinas, Rg; Obiols, Aq; Chavez, N; Ordonez, Ab; Argueta, S; Llerena, Gar; Sierra-Zorita, R; Arrieta, D; Hidalgo, Er; Saenz, R; Escalante, Mi; Morales, R; Calapaqui, W; Quezada, I; Arredondo, G; Agarwal, V; Aggarwal, R; Gupta, L. - In: RHEUMATOLOGY. - ISSN 1462-0324. - 62:10(2023), pp. 3291-3301. [10.1093/rheumatology/kead057]
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
Sebastiani, M;
2023-01-01
Abstract
Objective COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. Results We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs - OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs - OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
